• SP2509: Reframing LSD1 Targeting in AML

  2026-08-20

  SP2509 offers a mechanism-first strategy for acute myeloid leukemia research by combining selective LSD1 enzymatic inhibition with disruption of the LSD1-CoREST complex. This thought-leadership analysis connects chromatin biology, AML validation, assay design, combination strategy, and translational decision-making.

• Catalpol in Alzheimer’s Disease: Mechanisms and Evidence

  2026-08-19

  The 2022 review by Chen and colleagues integrates evidence that catalpol, an iridoid glycoside from Rehmannia glutinosa, may protect against Alzheimer’s disease through coordinated anti-inflammatory, antioxidant, antiapoptotic, and neuroprotective actions. Its main contribution is a mechanistic framework for interpreting catalpol’s multitarget effects while also highlighting the need for standardized models, dosing, and translational validation.

• Anti-p16 AFDC: Targeted Delivery and In Vitro Evidence

  2026-08-19

  The reference study develops a p16-targeting antibody fragment-drug conjugate that combines a humanized scFv, the S4 cell-penetrating peptide, and doxorubicin. Its selective activity in p16-high cancer cells and p16-positive TNBC organoids supports AFDCs as a promising preclinical strategy, while also highlighting the need for in vivo validation and careful biomarker qualification.

• DOPE as a Decision Tool for Lipid Delivery Assays

  2026-08-18

  1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is more than a membrane-fusion helper: it can determine how lipid delivery and redox assays should be designed and interpreted. This article connects DOPE formulation science with phospholipid-mediated ferroptosis research while defining the evidence boundaries between the two fields.

• Dual SMAD–Wnt Inhibition for iPSC-Derived RGCs

  2026-08-18

  The reference study developed a chemically defined, non-genetic method for directing induced pluripotent stem cells toward retinal ganglion cells through coordinated inhibition of SMAD and canonical Wnt signaling. The workflow improved reproducibility across experiments, produced more than 80% RGCs before enrichment, and achieved nearly 95% purity after Thy-1-based magnetic sorting.

• TK1 to S-Phase: Translational EdU Strategy in UCEC

  2026-08-17

  TK1 biology provides a compelling framework for studying proliferative endometrial cancer, but expression alone cannot resolve active DNA synthesis. This thought-leadership guide shows how EdU click chemistry and flow cytometry can convert TK1-associated hypotheses into quantitative, multiplexed translational evidence.

• In Vitro Drug Response Metrics in Cancer Research

  2026-08-17

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different relationships between growth inhibition and cell death. Its main practical contribution is a more discriminating framework for designing and interpreting in vitro cancer drug-response experiments.

• FAISL Stabilizes FAK in TNBC Metastasis

  2026-08-16

  The 2024 Advanced Science study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by preventing Calpain 2-mediated proteolysis. Its findings connect lncRNA-dependent control of FAK protein turnover with triple-negative breast cancer adhesion, growth, and metastasis, while also supporting FAISL-directed nanoparticle delivery as a preclinical strategy.

• From Thermal Shifts to Translational Biology

  2026-08-15

  A strategic guide to using the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) for mechanistic ligand discovery, pathway deconvolution, and translational prioritization. The article connects thermal shift assay principles with orthogonal validation across protease, kinase, apoptosis, cancer, and immunology workflows while distinguishing evidence from experimental hypotheses.

• Palonosetron: Precision for Translational CINV Research

  2026-08-15

  A mechanistic and strategic guide to using Palonosetron hydrochloride as a highly selective 5-HT3 receptor antagonist in receptor pharmacology, chemotherapy-induced nausea and vomiting prevention, radiotherapy-induced nausea and vomiting prevention, and OCT2 and MATE1 renal transporter inhibition studies.

• Cyclic di-GMP for Reliable Cell Assays

  2026-08-14

  A scenario-driven guide to using Cyclic di-GMP (SKU B7839) in viability, proliferation, cytotoxicity, STING, and biofilm research. It connects formulation data, assay controls, storage practice, and recent mechanistic evidence to improve interpretation and reproducibility.

• Methotrexate: From DHFR Biology to Translation

  2026-08-13

  Methotrexate is more than a familiar folate antagonist: its intracellular persistence, immune-cell selectivity, and permeability profile create both opportunities and decision points for translational research. This article connects DHFR biology, methotrexate polyglutamates, biomimetic permeability assays, and practical experimental design.

• Mubritinib (TAK 165): An OXPHOS Assay Framework

  2026-08-13

  Mubritinib (TAK 165) is best evaluated through a layered assay strategy that separates complex I inhibition from downstream cell death. This guide connects mitochondrial respiration, cancer-selective phenotypes, and lessons from comparative cardioprotection research to improve experimental interpretation.

• Chlorpromazine Beyond CNS: A Translational Lens

  2026-08-13

  Chlorpromazine is an established tool for dopamine receptor signaling, antipsychotic research, and antiemetic models. This thought-leadership perspective uses recent hepatic nanoparticle findings to show how carefully controlled pharmacological perturbation could strengthen translational study design without overstating an unvalidated cross-domain application.

• ATRX-Deficient Glioma: RTK Inhibitor Sensitivity

  2026-08-12

  The reference study identifies ATRX loss as a potential biomarker for increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its findings also support evaluating RTK inhibitor–temozolomide combinations while incorporating ATRX status into translational and clinical analyses.

447 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page